**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 56747

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Cohort Study***

**Exploring the safety and efficacy of adding ketoconazole to tacrolimus in pediatric renal transplant immunosuppression**

Méndez S *et al*. Safety and efficacy of adding ketoconazole to tacrolimus

Sindy Méndez, Brooke M Ramay, Angie Aguilar-González, Randall Lou-Meda

**Sindy Méndez, Angie Aguilar-González, Randall Lou-Meda,** Fundación para el Niño Enfermo Renal - FUNDANIER, Hospital Roosevelt Guatemala, Guatemala 01010, Guatemala

**Brooke M Ramay,** Department of Pharmaceutical Chemistry, Universidad del Valle de Guatemala, Guatemala 01015, Guatemala

**Author contributions:** Méndez S, Ramay BM, Aguilar-González A and Lou-Meda R conceptualized and designed the study, acquired, analyzed and interpreted data, supported drafting the article and making critical revisions; all the authors have given final approval of the version of the article to be published.

**Corresponding author: Brooke M Ramay, BSc, PharmD, Pharmacist, Professor,** Department of Pharmaceutical Chemistry, Universidad del Valle de Guatemala, 18 Avenida 11-95, Guatemala 01015, Guatemala. bramay@uvg.edu.gt

**Received:** May 15, 2020

**Revised:** June 18, 2020

**Accepted:** September 18, 2020

**Published online:**

**Abstract**

BACKGROUND

Guatemala is a developing country in Central America with limited health resources. In order to expand successful renal transplant care to children and adolescents at the lowest possible cost, our pediatric renal transplant clinic uses a post-transplant tacrolimus-sparing strategy *via* inhibition of CYP3A4.

AIM

To study the safety, efficacy and the associated cost reduction of ketoconazole in combination with tacrolimus in this pediatric population.

METHODS

A retrospective chart review was carried out among the cohort of pediatric renal transplant recipients treated at the Foundation for pediatric renal patients (Fundación para el Niño Enfermo Renal - FUNDANIER), a pediatric tertiary care renal transplant center in Guatemala City, Guatemala. Patient charts were reviewed to ascertain the number of transplant recipients who were transitioned from tacrolimus based immunosuppression to combination therapy with ketoconazole and tacrolimus. Twenty-five post-transplant patients that used ketoconazole combined with tacrolimus were identified. Anthropometric, clinical and laboratory data was collected from patient charts before and after the transition.

RESULTS

Of the 25 patient charts reviewed 12 (48%) patients were male and the average patient age was 13 years. Twenty-four (96%) transplants were from living donors. There was a non-significant difference between the mean tacrolimus doses six months and two months prior to ketoconazole: -0.10 ± 0.04 (95%CI: 0.007, -0.029), *P* = 0.23. However, the difference between the mean tacrolimus doses six months prior to ketoconazole initiation and six months after ketoconazole addition was significant: 0.06 ± 0.05 (95%CI: -0.034, -0.086) *P* < 0.001. All tacrolimus doses were reduced by 45% after the addition of ketoconazole. Therapeutic levels of tacrolimus ranged between 6.8-8.8 ng/mL during the study period and patients demonstrated an increase in estimated glomerular filtration rate. The combination of tacrolimus and ketoconazole resulted in a 21% reduction in cost.

CONCLUSION

Patients experienced an effective dose-reduction of tacrolimus with the administration of ketoconazole. There was no relevant variations in tacrolimus serum levels, number of rejections, or significant liver toxicity. The strategy allowed a cost reduction in pediatric immunosuppressive therapy.

**Key words:** Transplant; Immunosuppression; Tacrolimus; Ketoconazole; Pediatric; Chart review

Méndez S, Ramay BM, Aguilar-González A, Lou-Meda R. Exploring the safety and efficacy of adding ketoconazole to tacrolimus in pediatric renal transplant immunosuppression. *World J Transplant* 2020; In press

**Core tip:** In the most advanced stages of chronic kidney disease, transplantation improves patient survival. However, in low to middle income countries, transplantation is not feasible due to the high cost associated with transplant maintenance. Expenditures may be mitigated by pharmacokinetically boosting transplant medications. We present the addition of ketoconazole to post transplant regimens to boost therapeutic levels of tacrolimus, thus maintaining efficacy while reducing total daily doses. We found that therapeutic levels of tacrolimus were preserved during the study period, patients demonstrated an improvement in estimated glomerular filtration rate and a 21% reduction in medication cost.

**INTRODUCTION**

Treating pediatric patients with End-Stage Renal Disease (ESRD) in low to middle income countries is challenging[1-3]. Unfavorable socioeconomic conditions, insufficient numbers of pediatric clinics treating ESRD, limited access to medication, and clinics working with limited resources to treat patients with renal replacement therapy (RRT), all pose serious challenges for clinicians and patients with ESRD[1,4,5]. In addition to clinical challenges, government expenditures on health in Low to Middle Income Countries (LMIC) have been shown to range from 2.6% to 9% of the national Gross Domestic Product (GDP), a small fraction of each nation's income[1]. These clinical barriers to care, combined with paucity in national investment in RRT, result in a significant number of patients left without healthcare services treating RRT. Worldwide data show that over 2 million people are kept alive by RRT, the majority of whom are treated in only five countries (United States, Japan, Germany, Brazil, and Italy) constituting only 12% of the world´s population[6]. In contrast, only 20% are treated in about 100 LMIC that make up over 50% of the world's population[6]. For every 1 million population with ESRD, less than 100 are treated in LMIC countries. In contrast, more than 1000 per million population are treated in high income countries; the prevalence of RRT is higher in countries with higher incomes[7]. This depicts a clear and direct association between GDP and availability of RRT.

The population of Guatemala exceeds 16 million inhabitants, 61% of which are under the age of twenty one[8]. ESRD incidence in children in Guatemala is 4.6 per million age-related population (pmarp)[9,10]. As in other LMIC, clinics struggle to obtain the necessary resources to provide RRT for pediatric patients. The Foundation for Children with Kidney Diseases (FUNDANIER) was founded in 2007 in agreement with the Ministry of Health through Roosevelt Hospital, and created the first program providing free access to comprehensive RRT including transplantation, and immunosuppressive treatment, to Guatemalan children[9,10]. In our program we previously reported a patient population of 432 patients with chronic kidney disease (CKD) stage 2 or more. Of these, 193 were stage 5 CKD of whom 40% received peritoneal dialysis, 26.4% received hemodialysis, 12.4% received a transplant, and 17.6 % were managed without RRT[9].

Transplant clinics in developing countries other than Guatemala have similar goals and objectives in expanding successful renal transplant care at the lowest possible cost, and have reported the combined use of ketoconazole with low-dose tacrolimus to increase tacrolimus bioavailability through metabolic inhibition *via* P450 3A4[11-17]. Small short-term studies had previously supported such practice in Egypt, México, United States and India resulting in an annual cost savings of up to 60% in the immunosuppressive protocol while maintaining safety and efficacy of therapy in adults[11-14]. This combination has yet to be used in Central America where outcomes using the combination, especially in children, are still unknown[11,12].

The objective of this study was to identify the changes in tacrolimus dose and plasma concentration associated with the use of ketoconazole as a pharmacokinetic booster. We explore the safety, efficacy and the associated cost reduction of this combination in a retrospective cohort of children with kidney transplant in the FUNDANIER.

**MATERIALS AND METHODS**

After approval by the Research Ethics Committee at the Universidad del Valle de Guatemala (QF-010-febrero2015), we performed a retrospective evaluation of all pediatric renal recipients who received concomitant ketoconazole in tacrolimus-based immunosuppression in the FUNDANIER, a tertiary care renal transplant center in Guatemala. FUNDANIER carries out approximately 8-10 pediatric renal transplants per year in a population where patients are at, or below the national poverty line. Maintenance immunosuppressive treatment costs USD 725 per month for an average patient weighing 20 kg (this cost represents the average of protocol A and protocol B for a 20 kg-patient)[18-21].

At FUNDANIER, patients do not have to pay for transplant services and medications, as they are provided by the clinic. In order to achieve optimal cost benefit outcomes while maximizing patient coverage, immunosuppressive protocols are designed to treat patients at the lowest possible price[22-27].  For example, initial post-transplant protocol calls for use of tacrolimus, mycophenolate and prednisone (protocol A) after completing one year on maintenance therapy at FUNDANIER, mycophenolate is replaced by azathioprine, a more affordable immunosuppressive medication (protocol B).  With this intervention, FUNDANIER has improved the access to maintenance immunosuppressive therapy, reducing the cost by 40%. For example, replacing protocol A with protocol B in a patient who weighs 20 kg results in a cost reduction from USD 904 per month to USD 544 per month[18-21]. These types of changes to immunosuppressive regimens have been used at FUNDANIER to successfully overcome budget constraints and more effectively provide medication to patients.

We carried out a retrospective observational study, with a pre-post single arm design[22] collecting information from 2011 to 2015 from a cohort of patient records stored in the FUNDANIER database before and after the addition of ketoconazole to the usual immunosuppressive protocol. Inclusion criteria for chart review were: age younger than 18 years old, at least 3 mo in the program post-transplantation currently on the tacrolimus protocol, and switched to ketoconazole/tacrolimus combination during their outpatient transplant clinic attendance. Charts were reviewed to identify the point at which ketoconazole was added to the post-transplant treatment. A total of six documented visits were reviewed for each patient chart during the study: 3 visits prior to ketoconazole initiation and 3 visits after the combination was initiated. An average of 2 mo between each visit was documented.

Based on the pediatric nephrology service protocol, all patients in the chart review initially received the following maintenance immunosuppressive treatment (“protocol A”): tacrolimus (0.1-0.3 mg/kg/d), mycophenolate (1200 mg/m2/d) and prednisone (5 mg/d). Ketoconazole suspension (100 mg/5 mL) at a dose of 1.5 mg/kg/d in one dose per 24 h was added to the immunosuppressive treatment (Ketospor Qualipharm®) during the period of 2011-2015. Patients were instructed not to take macrolides or grapefruit at the time of the study.

Outcome measures obtained from patient charts were: (1) Tacrolimus dose/kg; (2) Serum tacrolimus levels (taken at hospital laboratory by the electrochemiluminescence (ECL) method and documented in charts); (3) Estimated glomerular filtration rate (eGFR) was estimated by the Schwartz formula[22] through creatinine measured by the Jaffe method; (4) Graft rejection, defined by the transplant team at the hospital as biopsy findings or a 50% elevation in serum creatinine without apparent cause, and with a favorable response to treatment with steroids; (5) Ketoconazole hepatotoxicity was defined as an increase in liver enzymes greater than twice the normal value compared to the reference laboratory (transaminases); and (6) Cost difference of immunosuppressive treatment.

***Data analysis***

Descriptive statistics were used to define the tacrolimus dose and serum concentration for each patient and for the entire population before, and after initiating therapy with ketoconazole. eGFR values were calculated during follow-up for graft stability and function. The number of graft rejection episodes before and after ketoconazole were reported, additionally, the number of cases where transaminases were two times the normal limit compared to laboratory reference values during ketoconazole combination were monitored and used as an indication of toxicity. The cost of immunosuppressive treatment is reported prior to and after ketoconazole use.

Mean differences in the dose of tacrolimus and eGFR before and after addition of ketoconazole were compared using the paired student’s *t*-test. Statistical significance was defined using a 95% confidence interval and *p* values less than 0.05.

**RESULTS**

According to the FUNDANIER database in 2015, twenty-five post-transplant patients used ketoconazole combined with tacrolimus. Twelve (48%) patients were male and the average age of the patients was 13 years. Ninety six percent of transplants were from living donors with a mean follow-up of 18.5 mo (± 20).

***Tacrolimus dose and serum concentrations***

The average recorded tacrolimus weight-based doses at six, four and two months prior to ketoconazole initiation were 0.13 mg/kg/d; 0.12 mg/kg/d; and 0.11 mg/kg/d, respectively. The average recorded tacrolimus weight-based doses at two, four and six months post-ketoconazole initiation were 0.09 mg/kg/d; 0.07 mg/kg/d; and 0.06 mg/kg/d, respectively.

The mean tacrolimus blood levels at six, four and two months prior to ketoconazole initiation were: 7.4 ± 2.6 ng/dL; 7.4 ± 2.5 ng/dL; and 7.4 ± 2.6 ng/dL, respectively. The mean tacrolimus blood levels recorded at two, four and six month visits post-ketoconazole initiation were:  8.8 ± 4.9 ng/dL; 6.9 ± 3.6 ng/dL; and 6.8 ± 3.2 ng/dL, respectively (Table 1).

There was a non-significant difference between the mean tacrolimus doses at six months and two months prior to ketoconazole:  -0.10 ± 0.04 (95%CI: 0.007, -0.029), *P* = 0.23. However, the difference between the mean tacrolimus doses six months prior to ketoconazole initiation and six months after ketoconazole addition was significant: 0.06 ± 0.05 (95%CI: -0.034, -0.086) *P* < 0.001.

There were no observed fluctuations in the blood levels of tacrolimus among patients during the visits before the combination, as compared to after the combination with ketoconazole (Table 1). None of the patient charts documented a variation in serum transaminase levels during the visits pertaining to use of the ketoconazole-tacrolimus combination. Overall, a reduction in tacrolimus dose was observed.  The mean tacrolimus dose reduction was 45% (± 25%) after the addition of ketoconazole.

***Renal function***

The mean eGFR before the addition of ketoconazole was 69.2 (± 29.7) mL/min/1.73 m2 and after the initiation of ketoconazole was 66.4 (± 23) mL/min/1.73 m2. Changes in eGFR were not significant (*P* = 0.062) (Table 1). However, patients demonstrated an increased eGFR level from 2 mo prior to the combination and 6 mo post-combination during the study period (*P <* 0.050).

***Graft rejections***

10 rejection episodes were reported during the study, the majority of which were reported before initiation of ketoconazole. Eight of ten cases (80%) were reported before the combination of ketoconazole and 2 of 10 (20%) episodes after the addition of ketoconazole to tacrolimus (Table 1).

***Cost savings***

The combination of tacrolimus and ketoconazole resulted in a substantial cost saving. The immunosuppressive therapy cost dropped from USD 872 (SD, 168) per patient to USD 691 (SD, 128) per patient. Given the variation in patient weight and the resulting associated cost of treatment, the mean cost reduction for the sample was 21% (SD, 17).  This includes 18 patients with a reduction in cost ranging from (21%-42%), 6 patients with no change in cost (0%) and 1 patient with an increase in cost (+27%).

**DISCUSSION**

The combination of tacrolimus and ketoconazole resulted in a substantial tacrolimus dose reduction (45% reduction) while maintaining therapeutic levels (5-7 ng/mL) in pediatric transplant patients at FUNDANIER. Findings from this chart review are similar to other reports where the combination has been used in adults[15-18,20,23-26]. In one study from Mexico, eleven patients using the ketoconazole-tacrolimus combination post-transplant were followed for 15 mo (± 10 mo), and demonstrated a 78% dose reduction in tacrolimus while maintaining therapeutic immunosuppressive levels[25]. el-Dahshan *et al*[15], described a 59% reduction in the tacrolimus dose after six months of therapy in 70 Egyptian post-transplant patients. These patients ranged in age from 16 to 45 years and demonstrated therapeutic tacrolimus levels upon using the ketoconazole combination[20]. After two years of therapy, the same Egyptian cohort successfully maintained immunosuppressive therapy using a reduced dose at 53.8% of the normal tacrolimus dose compared to the control group[27]. Elamin *et al*[13] also reported a 63% median tacrolimus dose reduction, ranging from 50% to 83% in 30 Sudan patients. The mean age of these patients was 36 ± 12 years. During the one-year follow-up, tacrolimus remained in the therapeutic range, between 5-7 ng/mL. The differences in mean tacrolimus dose showed no significant variation upon ketoconazole initiation, nevertheless, 6 mo after initiation of the combination, there was a significant decrease in the tacrolimus dose. Here we describe the successful use of tacrolimus combined with ketoconazole in a population of pediatric transplant patients.

In our study, none of the patients in the ketoconazole group experienced a decrease in eGFR. We observed an improvement in eGFR when we compared the last visit of patients on the ketoconazole combination and the visit before the combination (*P* < 0.001). Improvements in graft function with the addition of ketoconazole have been reported in previous studies[18,26] suggesting that a reduction in tacrolimus dose decreases the risk and prevalence of tacrolimus nephrotoxicity. Studies have demonstrated that improvement in eGFR leads to an increase in patient graft survival, and a reduction in graft loss[28,29], we therefore expect that patients using the ketoconazole-tacrolimus combination have an equally high chance of graft survival compared to patients on usual doses of tacrolimus.

In our study, the rejection rate remained unchanged during treatment with the combination of ketoconazole and tacrolimus. However, other similar studies have demonstrated an increase in rejection rates in patients exposed to the combination of ketoconazole and tacrolimus when these patients have a high immunological risk, for example, those with African ethnicity, transplant recipients from cadaveric donors, and previously sensitized patients[16]. We found that the number of rejections did not differ before and after drug combination, most likely because the patient population at FUNDANIER fits into a low immunological risk group characterized as transplant recipients from living donors, HLA compatible and non-sensitized patients. Most importantly, stability in graft function did not fluctuate with the use of combination therapy.

In 2013, the United States Food and Drug Administration and the “Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)” issued a restriction on ketoconazole use due to side effects, primarily hepatotoxicity and adrenal gland insufficiency[21]. Restrictions on ketoconazole were initiated in Guatemala several years later (after this study, 2016), but no policy changes in Guatemala regarding ketoconazole use in adults or children have been made. Despite these warnings and restrictions, we found no hepatotoxicity in our study and this is likely attributed to the small doses used in our pediatric population (1.3 mg/kg/d)[30,31]. Of note, tacrolimus itself is known to cause an increase in transaminases[32], therefore our patients may have been protected by the dose reduction of tacrolimus with the combination of ketoconazole. Findings from our observational study may be supported by larger experimental studies in order to draw conclusions regarding the safety of ketoconazole.

The combination of tacrolimus and ketoconazole resulted in substantial cost savings while preserving the safety profile for our post-transplant patients[16,24,26]. Other similar studies, from Sudan, United Kingdom and Egypt have shown substantial cost reductions, ranging from 52% to 60% when using the combination[15,18,20]. As in many other LMIC, the small percent of GDP dedicated to health care in Guatemala compromises the local government’s ability to provide transplant medication to the population. Cost reduction in transplant medications helps to mitigate barriers in treatment access[33]. Within the socioeconomic setting of FUNDANIER, 18 of 25 patients experienced a cost reduction allowing the clinic to treat a greater number of transplant patients.

We recognize the limitations of this study which are typical of retrospective chart reviews carried out with few patients during short periods of time. For example, liver function tests were the only values recorded from patient charts to document the side effects of ketoconazole use.  Metabolic and adrenal side effects, that may be the result of ketoconazole use, were not documented in this study. Nevertheless, if serious adverse events due to ketoconazole use had occurred (*i.e.*, metabolic adverse events, abnormalities in EKG), they would have been reported to the equivalent of the regulatory department in Guatemala and documented within this study. Also, our study represents a small proportion of patients who receive renal transplants in the LMIC setting and may not be representative of all patients in other countries. In the FUNDANIER clinic population, the safety and efficacy of tacrolimus and ketoconazole have been successfully observed in pediatric post-renal transplant patients demonstrating a significant cost reduction.  However, larger studies need to be carried out to capture broad safety and efficacy profiles in this patient population. These types of interventions are of added benefit in the LMIC setting where access to medications post-transplant is problematic.

**CONCLUSION**

Patients experienced an effective dose-reduction of tacrolimus with the administration of ketoconazole. No relevant variations in tacrolimus serum levels, number of rejections, or significant liver toxicity were observed. This allowed a significant cost reduction in the use of pediatric immunosuppressive therapy.

**ARTICLE HIGHLIGHTS**

***Research background***

Transplant clinics in developing countries continually aim to provide successful renal transplant care at the lowest possible cost, and have reported that the combined use of ketoconazole with low-dose tacrolimus increases tacrolimus bioavailability through metabolic inhibition *via* P450 3A4.

***Research motivation***

This combination has been used successfully in adult transplant patients, but has not been demonstrated in pediatric patients. In order to expand successful renal transplant care to children and adolescents at the lowest possible cost, our pediatric renal transplant clinic uses a post-transplant tacrolimus-sparing strategy *via* inhibition of CYP3A4.

***Research objectives***

The objective of this study was to identify the changes in tacrolimus dose and plasma concentration associated with the use of ketoconazole as a pharmacokinetic booster. We describe the safety, efficacy and the associated cost reduction of this combination from a retrospective cohort of children with a kidney transplant in the FUNDANIER.

***Research methods***

We carried out a retrospective observational study, with a pre-post single arm design collecting information from 2011 to 2015 from a cohort of patient records stored in FUNDANIER database before and after the addition of ketoconazole to the usual immunosuppressive protocol. Inclusion criteria for chart review were: age younger than 18 years, at least 3 mo post-transplantation, currently on the tacrolimus protocol, and switched to ketoconazole/tacrolimus combination during their outpatient transplant clinic attendance. Charts were reviewed to identify the point at which ketoconazole was added to the post-transplant treatment. A total of six documented visits were reviewed for each patient chart during the study: 3 visits prior to ketoconazole initiation and 3 visits after the combination was initiated. An average of 2 mo between each visit was documented.

***Research results***

Of the 25 patient charts reviewed, 12 (48%) patients were male and the average age of the patients was 13 years. Twenty-four (96%) transplants were from living donors. There was a non-significant difference between the mean tacrolimus doses six months and two months prior to ketoconazole:  -0.10 ± 0.04 (95%CI: 0.007, -0.029), *P* = 0.23. However, the difference between the mean tacrolimus doses six months prior to ketoconazole initiation and six months after ketoconazole addition was significant: 0.06 ± 0.05 (95%CI: -0.034, -0.086) *P* < 0.001. All tacrolimus doses were reduced by 45% after the addition of ketoconazole. Therapeutic levels of tacrolimus were preserved during the study period and patients demonstrated an improvement in eGFR. The combination of tacrolimus and ketoconazole resulted in a 21% reduction in cost.

***Research conclusions***

Patients experienced an effective dose-reduction of tacrolimus with the administration of ketoconazole. No relevant variations in tacrolimus serum levels, number of rejections, or significant liver toxicity were observed. This allowed for a safe, efficacious, and significant cost reduction in pediatric immunosuppressive therapy.

***Research perspectives***

In the FUNDANIER clinic population, the safety and efficacy of tacrolimus and ketoconazole were successfully observed in pediatric post-renal transplant patients demonstrating a significant cost reduction.  However, larger studies need to be carried out to capture broad safety and efficacy profiles in this patient population. These types of interventions are of added benefit in the low to middle income countries setting where access to medications post-transplant is problematic.

**ACKNOWLEDGEMENTS**

The authors gratefully acknowledge the detailed review and helpful comments provided by Dr. Alejandro Cerón and Marilia Fuentes for her contributions in data collection.

**REFERENCES**

1 **Rizvi SA**, Sultan S, Zafar MN, Naqvi SA, Lanewala AA, Hashmi S, Aziz T, Hassan AS, Ali B, Mohsin R, Mubarak M, Farasat S, Akhtar SF, Hashmi A, Hussain M, Hussain Z. Pediatric kidney transplantation in the developing world: challenges and solutions. *Am J Transplant* 2013; **13**: 2441-2449 [PMID: 23865679 DOI: 10.1111/ajt.12356]

2 **Warady BA**, Chadha V. Chronic kidney disease in children: the global perspective. *Pediatr Nephrol* 2007; **22**: 1999-2009 [PMID: 17310363 DOI: 10.1007/s00467-006-0410-1]

3 **Wetmore JB,** Collins AJ. Global challenges posed by the growth of end-stage renal disease. *Ren Replace Ther* 2016; **2**: 15 [DOI: 10.1186/s41100-016-0021-7]

4 **Freeman MA**, Myaskovsky L. An overview of disparities and interventions in pediatric kidney transplantation worldwide. *Pediatr Nephrol* 2015; **30**: 1077-1086 [PMID: 25315177 DOI: 10.1007/s00467-014-2879-3]

5 **Gulati S**, Kumar A, Sharma RK, Gupta A, Bhandari M, Kumar A, Srivastava A. Outcome of pediatric renal transplants in a developing country. *Pediatr Nephrol* 2004; **19**: 96-100 [PMID: 14648338 DOI: 10.1007/s00467-003-1316-9]

6 **Couser WG**, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. *Kidney Int* 2011; **80**: 1258-1270 [PMID: 21993585 DOI: 10.1038/ki.2011.368]

7 **Bello AK**, Levin A, Tonelli M, Okpechi IG, Feehally J, Harris D, Jindal K, Salako BL, Rateb A, Osman MA, Qarni B, Saad S, Lunney M, Wiebe N, Ye F, Johnson DW. Assessment of Global Kidney Health Care Status. *JAMA* 2017; **317**: 1864-1881 [PMID: 28430830 DOI: 10.1001/jama.2017.4046]

8 **Instituto Nacional de Estadística (INE).** Proyecciones de Población 2000-2020 con base al Censo 2002, Guatemala. [Internet] 2017. Available from: <https://www.ine.gob.gt/sistema/uploads/2014/02/20/jZqeGe1H9WdUDngYXkWt3GIhUUQCukcg.pdf>

9 **Lou-Meda R**. Comprehensive approach to pediatric kidney diseases in Guatemala. *Clin Nephrol* 2015; **83**: 82-84 [PMID: 25725248 DOI: 10.5414/CNP83S082]

10 **Cerón A**, Fort MP, Morine CM, Lou-Meda R. Chronic kidney disease among children in Guatemala. *Rev Panam Salud Publica* 2014; **36**: 376-382 [PMID: 25711748]

11 **Zhang R**. Modern Immunosuppressive Therapy in Kidney Transplantation. *Open J Organ Transpl Surg* 2013; **3**: 22-31 [DOI: 10.4236/ojots.2013.32005]

12 **el-Agroudy AE**, Sobh MA, Hamdy AF, Ghoneim MA. A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up. *Transplantation* 2004; **77**: 1371-1376 [PMID: 15167592 DOI: 10.1097/01.TP.0000121133.84763.26]

13 **Elamin S**, El-Magzoub AR, Dablouk N, Mahmoud F, Abbas M. Co-administration of ketoconazole and tacrolimus to kidney transplant recipients: cost minimization and potential metabolic benefits. *Saudi J Kidney Dis Transpl* 2014; **25**: 814-818 [PMID: 24969193 DOI: 10.4103/1319-2442.135033]

14 **Khan E**, Killackey M, Kumbala D, LaGuardia H, Liu YJ, Qin HZ, Alper B, Paramesh A, Buell J, Zhang R. Long-term outcome of ketoconazole and tacrolimus co-administration in kidney transplant patients. *World J Nephrol* 2014; **3**: 107-113 [PMID: 25332902 DOI: 10.5527/wjn.v3.i3.107]

15 **el-Dahshan KF**, Bakr MA, Donia AF, Badr Ael-S, Sobh MA. Co-administration of ketoconazole to tacrolimus-treated kidney transplant recipients: a prospective randomized study. *Nephrol Dial Transplant* 2004; **19**: 1613-1617 [PMID: 15034161 DOI: 10.1093/ndt/gfh191]

16 **Chandel N**, Aggarwal PK, Minz M, Sakhuja V, Kohli KK, Jha V. CYP3A5\*1/\*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole. *Pharmacogenet Genomics* 2009; **19**: 458-463 [PMID: 19384264 DOI: 10.1097/FPC.0b013e32832bd085]

17 Sistema de Información de Contrataciones y adquisiciones del Estado, Guatecompras. [Internet] 2018. Available from: http://www.guatecompras.gob.gt/concursos/consultaCon curso.aspx?nog=7876645o=5

18 Sistema de Información de Contrataciones y adquisiciones del Estado, Guatecompras. [Internet] 2018. Available from: http://www.guatecompras.gob.gt/concursos/consultaCon curso.aspx?nog=7889461o=4

19 Sistema de Información de Contrataciones y adquisiciones del Estado, Guatecompras. [Internet] 2018. Available from: http://www.guatecompras.gob.gt/concursos/consultaCon curso.aspx?nog=7909233o=5

20 Sistema de Información de Contrataciones y adquisiciones del Estado, Guatecompras. [Internet] 2018. Available from: http://www.guatecompras.gob.gt/Ofertas/DetalleOferta.aspx?nog=78 63926o=4

21 **Yao G**, Albon E, Adi Y, Milford D, Bayliss S, Ready A, Raftery J, Taylor RS. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. *Health Technol Assess* 2006; **10**: iii-iiv, ix-xi, 1-157 [PMID: 17134597 DOI: 10.3310/hta10490]

22 **Schwartz GJ**, Work DF. Measurement and estimation of GFR in children and adolescents. *Clin J Am Soc Nephrol* 2009; **4**: 1832-1843 [PMID: 19820136 DOI: 10.2215/CJN.01640309]

23 **Thiese MS**. Observational and interventional study design types; an overview. *Biochem Med (Zagreb)* 2014; **24**: 199-210 [PMID: 24969913 DOI: 10.11613/BM.2014.022]

24 **Floren LC**, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. *Clin Pharmacol Ther* 1997; **62**: 41-49 [PMID: 9246018 DOI: 10.1016/S0009-9236(97)90150-8]

25 **Soltero L**, Carbajal H, Rodríguez-Montalvo C, Valdés A. Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects. *Transplant Proc* 2003; **35**: 1319-1321 [PMID: 12826147 DOI: 10.1016/S0041-1345(03)00450-0]

26 **Vivekanand J**. Current status of end-stage renal disease care in India and Pakistan. *Kidney Int Suppl* 2013; **3**: 157-160 [DOI: 10.1038/kisup.2013.3]

27 **El-Dahshan KF**, Bakr MA, Donia AF, Badr Ael-S, Sobh MA. Ketoconazole-tacrolimus coadministration in kidney transplant recipients: two-year results of a prospective randomized study. *Am J Nephrol* 2006; **26**: 293-298 [PMID: 16804292 DOI: 10.1159/000094133]

28 **Clayton PA**, Lim WH, Wong G, Chadban SJ. Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants. *J Am Soc Nephrol* 2016; **27**: 3440-3446 [PMID: 27059513 DOI: 10.1681/ASN.2015050524]

29 **First MR**. Renal function as a predictor of long-term graft survival in renal transplant patients. *Nephrol Dial Transplant* 2003; **18 Suppl 1**: i3-i6 [PMID: 12738756 DOI: 10.1093/ndt/gfg1027]

30 **Agencia española de medicamentos y productos sanitarios (AEMPS)**. Ketoconazol de administración sistémica (comprimidos): suspensión de comercialización. [Internet]. 2013. Available from: [https://www.aemps.gob.es/informa/notasInformativas/medicamentosUso Humano/seguridad/2013/NI-MUH\_FV\_21-2013-ketoconazol.htm](https://www.aemps.gob.es/informa/notasInformativas/medicamentosUso%20Humano/seguridad/2013/NI-MUH_FV_21-2013-ketoconazol.htm)

31 **Janssen Pharmaceuticals Inc. Food and Drug Administration**. Nizoral (Ketoconazole). [Internet] 2014. Available from: [https://www.fda.gov/downloads/Drugs/DrugSafety/UCM 362592.pdf](https://www.fda.gov/downloads/Drugs/DrugSafety/UCM%20362592.pdf)

32 **CrossTech Communications Inc**. Patient information about Protropic (tacrolimus). [Internet]. July 2003. Available from: [https://www.accessdata.fda.gov/drugsatfda\_docs /Lab el/2003/50777scs006\_protopic \_lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs%20/Lab%20el/2003/50777scs006_protopic%20_lbl.pdf)

33 **Ramay BM**, Cerón A, Méndez-Alburez LP, Lou-Meda R. Factors associated to acceptable treatment adherence among children with chronic kidney disease in Guatemala. *PLoS One* 2017; **12**: e0186644 [PMID: 29036228 DOI: 10.1371/journal.pone.0186644]

**Footnotes**

**Institutional review board statement:** The Research Ethics Committee from the Faculty of Humanities and Science, at the Universidad del Valle de Guatemala reviewed and approved the study protocol and all study documents (QF-010-febrero2015).

**Informed consent statement:** Researchers did not collect any personal identifiers to carry out this retrospective chart review. Informed consent was waived and approved by the ethics committee.

**Conflict-of-interest statement:** The authors have no conflicts of interest to report.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** May 15, 2020

**First decision:** May 24, 2020

**Article in press:**

**Specialty type:** Transplantation

**Country/Territory of origin:** Guatemala

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): E

1. **Reviewer:** Eleftheriadis T, Tanaka H, Trkulja V **S-Editor:** Gong ZM **L-Editor:** Webster JR **P-Editor:**

**Table 1 Outcome measures**

|  |  |  |
| --- | --- | --- |
| **Outcome measures**  | **Documented visits reviewed: tacrolimus alone**  | **Documented visits reviewed: tacrolimus + ketoconazole combination** |
| **6 mo, mean (SD)** | **4 mo, mean (SD)** | **2 mo, mean (SD)** | **2 mo, mean (SD)** | **4 mo, mean (SD)** | **6 mo, mean (SD)** |
| Tacrolimus dose (mg/kg/d) | 0.13 (0.04) | 0.12 (0.05) |  0.11 (0.05) |  0.09 (0.05)1 |  0.07 (0.03)1 |  0.06 (0.03)1 |
| Tacrolimus blood levels (ng/ml) | 7.4 (2.6) | 7.4 (2.5) | 7.4 (2.6) | 8.8 (4.9) | 6.9 (3.6) | 6.8 (3.2) |
| eGFR (1.73 ml/min/1.73 m2) | ---- | ---- | 69.2 (29.7)1 | 63.6 (21.4) | 64.2 (2.10) | 71.2 (27.6)1 |

1*t*-test, statistically significant when *P <* 0.05. SD: Standard deviation; eGFR: Estimated glomerular filtration rate.